Zervimesine (, ; developmental code name CT-1812 or CT1812; tentative brand name Elayta) is a sigma-2 receptor antagonist which is under development for the treatment of Alzheimer's disease, dementia, dry age-related macular degeneration, and other indications.
The sigma-2 receptor is a binding site for ò-amyloid oligomers. Zervimesine has been found to diplace ò-amyloid oligomers from the sigma-2 receptor in both preclinical and clinical studies. As of 2024, effectiveness data on zerimesine for treatment of Alzheimer's disease are still lacking.
Zervimesine is under development by Cognition Therapeutics. As of July 2025, it is in phase 2 clinical trials for Alzheimer's disease, dementia, and dry age-related macular degeneration and is in preclinical research for Parkinson's disease. The drug was also being developed for treatment of other cognition disorders, but development for this indication was discontinued.